[Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Board of Directors and Corporate Executive Committee in Spring 2023
Christoph Franz has decided not to seek re-election to the Board of Directors at the Annual General Meeting (AGM) in March 2023The Board of Directors intends to proposeSeverin Schwan as new Chairman at the Annual General MeetingThe Board of Directors has appointed ThomasSchinecker as the new Roche CEO effective 15 March 2023Basel, 21 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Christoph Franz has decided not to seek re-election to the Board of Directors at the AGM in March 2023. The Board of Directors intends to propose Severin Schwan as new Chairman at the AGM and has appointed Thomas Schinecker as...
Source: Roche Investor Update - July 21, 2022 Category: Pharmaceuticals Source Type: news
Physiology Is Vital to Precision Medicine in Acute Respiratory Distress Syndrome and Sepsis.
The American Thoracic Society recently released a thoughtful and forward-thinking statement outlining a research agenda for precision medicine in sepsis and acute respiratory distress syndrome (ARDS). The statement draws attention to the problem of highly variable treatment responsiveness in these heterogeneous syndromes and proposes a range of promising solutions to address this problem, with a focus on enhanced molecular phenotyping and novel trial designs ( 2 External 0 0 0 ref showRefEvent 1 false https://www.atsjournals.org/doi/10.1164/rccm.202202-0230ED?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%...
Source: Current Awareness Service for Health (CASH) - July 12, 2022 Category: Consumer Health News Source Type: news
---
Dr. Rick Klausner discusses his work in cell and molecular biology, immunology and human genetics. For more Life Itself talks and articles visit here. (Source: CNN.com - Health)
Source: CNN.com - Health - July 11, 2022 Category: Consumer Health News Source Type: news
Krogan elected to the European Molecular Biology Organization
Esteemed UCSF scientist joins leading scientific research group (Source: UCSF School of Pharmacy News)
Source: UCSF School of Pharmacy News - July 11, 2022 Category: Universities & Medical Training Source Type: news
Historical anatomical collections of human remains: exploring their reinterpretation as representations of racial violence - Zuckerman MK, Austin RM, Hofman CA.
We synthesize how the tools of molecular anthropology, integrated with analyses of skeletal material, can provide direct insights into the context-specific experiences of racial structural violence in the past. Our work--which is emblematic of how biologic... (Source: SafetyLit)
Source: SafetyLit - July 4, 2022 Category: International Medicine & Public Health Tags: Jurisprudence, Laws, Legislation, Policies, Rules Source Type: news
How Jennifer Doudna ’s Life Has Changed Since Discovering CRISPR 10 Years Ago
Jennifer Doudna was staring at a computer screen filled with a string of As, Cs, Ts, and Gs—the letters that make up human DNA—and witnessing a debilitating genetic disease being cured right before her eyes. Just a year earlier, in 2012, she and microbiologist Emmanuelle Charpentier had published a landmark paper describing CRISPR-Cas9, a molecular version of autocorrect for DNA, and she was seeing one the first demonstrations of CRISPR’s power to cure a human disease. She was in the lab of Dr. Kiran Musunuru, a Harvard researcher who was eager to show her the results from an experiment he had just finish...
Source: TIME: Health - July 1, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized feature Genetics healthscienceclimate Source Type: news
Scientists are still fleshing out Darwin ’s theory of evolution | Letters
There can be no one unifying theory, writesProf Jonathan Bard, while Nicholas Maxwelllooks to the role of purposive actions andPete Bibbysays the fittest theory will surviveStephen Buranyi misses some key points in his article (Do we need a new theory of evolution?, 28 June). Darwin saw novel speciation as resulting from natural selection acting on anatomical variants, but that simple skeleton needed fleshing out. It took a century of research, for example, for us to understand the importance of inheritance in very small populations if novel variants were to become predominant.The major problems in understanding evolutiona...
Source: Guardian Unlimited Science - July 1, 2022 Category: Science Authors: Letters Tags: Evolution Science Charles Darwin Biology UK news Physics Source Type: news
Scientists pinpoint new brain target for antinausea drugs
Whether we’ve got the flu or have had too much to drink, most of us have experienced nausea. Unlike other universal sensations such as hunger and thirst, however, scientists still don’t understand the biology behind the feeling—or how to stop it. A new study in mice identifies a possible key player: specialized brain cells that communicate with the gut to turn off the feeling of nausea.
It’s an “elegant” study, says Nancy Thornberry, CEO of Kallyope, a biotechnology company focused on the interplay between the gut and the brain. Further research is needed to translate the finding into antinausea therapies...
Source: ScienceNOW - June 29, 2022 Category: Science Source Type: news
Vanderbilt University names John Kuriyan dean of the School of Medicine Basics
The new dean, one of the world ’s top structural biologists, will be tasked with expanding the university’s global research by using molecular, cellular and developmental biology to advance drug, pharmacology and genetic engineering. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 21, 2022 Category: Biotechnology Authors: Joel Stinnett Source Type: news
Save the Date: NCBI at the Bioinformatics Open Science Conference (BOSC), July 2022
Come visit NCBI at the Bioinformatics Open Science Conference (BOSC), part of the Intelligent Systems for Molecular Biology Conference (ISMB), July 13-16, taking place both in person in Madison, Wisconsin and virtually! We’ll be presenting talks and posters on the latest updates to the NCBI Datasets, BLAST, and Protein resources. You can also join us at … Continue reading Save the Date: NCBI at the Bioinformatics Open Science Conference (BOSC), July 2022 →
The post Save the Date: NCBI at the Bioinformatics Open Science Conference (BOSC), July 2022 appeared first on NCBI Insights. (Source: NCBI Insights)
Source: NCBI Insights - June 16, 2022 Category: Databases & Libraries Authors: NCBI Staff Tags: What's New Basic Local Alignment Search Tool (BLAST) CGR Datasets ElasticBLAST iCn3D Protein Source Type: news
Arati Prabhakar set to become Biden ’s science adviser and his pick to lead science office
Some content has been removed for formatting reasons. Please view the original article for the best reading experience.
In 1993, then-President Bill Clinton picked a 34-year-old applied physicist named Arati Prabhakar to lead the National Institute of Standards and Technology (NIST). Two decades later, former President Barack Obama chose her to lead the Defense Advanced Research Projects Agency (DARPA). And as soon as this week, President Joe Biden is expected to name Prabhakar as his science adviser and nominate her as director of the White House Office of Science and Technology Policy (OSTP).
The 63-year-old ...
Source: ScienceNOW - June 13, 2022 Category: Science Source Type: news
Katharina H öfer Probes the Machinery of Bacterial Gene Expression
The molecular biologist studies how chemical modifications to RNA building blocks change the way RNA regulates complex cellular processes. (Source: The Scientist)
Source: The Scientist - June 13, 2022 Category: Science Tags: Scientist to Watch Magazine Issue Source Type: news
Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab cohort of the Phase 1b TriMM-2 study (NCT04108195). Teclistamab, an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA) is being studied in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 Patients in the study, including a high proportion with prior anti-CD38 exposur...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA ® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations
CHICAGO, ILLINOIS, June 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the pivotal Phase 2 RAGNAR study evaluating the investigational use of BALVERSA® (erdafitinib), a fibroblast growth factor receptor (FGFR) kinase inhibitor, in patients with advanced solid tumors with prespecified FGFR alterations. At a planned interim analysis (IA), responses were observed across a variety of FGFR-driven solid tumors for patients who had exhausted standard treatment options prior to being treated with BALVERSA®.[1] These results will be featured in an oral presentation (...
Source: Johnson and Johnson - June 7, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Updated Data for Janssen ’s Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 5, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/2 MajesTEC-1 study. Teclistamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA), which is being studied in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 The data were featured as part of an oral session during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Additional poster presentations f...
Source: Johnson and Johnson - June 5, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
